We started our analysis with the two most important genes associated with sensitivity to PARPis: BRCA1 and BRCA2. Both genes’ germline mutations have been linked to an increased risk of several human malignancies, including breast and ovarian cancers. The gene discussed is BRCA2; the disease is ovarian carcinoma.